Somac Control

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

pantoprazole

Available from:

Takeda GmbH

ATC code:

A02BC02

INN (International Name):

pantoprazole

Therapeutic group:

Inibituri tal-Proton pump

Therapeutic area:

Reflux gastroesofagi

Therapeutic indications:

Trattament fuq medda qasira ta 'żmien ta' sintomi ta 'rifluss (e. ħruq ta 'stonku, riġenerazzjoni tal-aċidu) fl-adulti.

Product summary:

Revision: 16

Authorization status:

Awtorizzat

Authorization date:

2009-06-12

Patient Information leaflet

                                22
B. FULJETT TA’ TAGĦRIF
23
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
SOMAC CONTROL 20 MG PILLOLI GASTRO-REŻISTENTI
pantoprazole
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
Dejjem ħu din il-mediċina eżatt kif deskritt f’dan il-fuljett jew
kif qallek it-tabib jew l-ispiżjar tiegħek.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Staqsi lill-ispiżjar tiegħek jekk tkun trid aktar informazzjoni jew
pariri.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
-
Jekk ma tħossokx aħjar jew jekk tmur għall-agħar għandek tkellem
tabib wara ġimagħtejn.
-
M’għandekx tieħu l-pilloli SOMOC Control għal iktar minn 4
ġimgħat mingħajr ma tkellem
tabib.
F’DAN IL-FULJETT
1.
X’inhu SOMAC Control u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu SOMAC Control
3.
Kif għandek tieħu SOMAC Control
4.
Effetti sekondarji possibbli
5.
Kif taħżen SOMAC Control
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU SOMAC CONTROL U GĦALXIEX JINTUŻA
SOMAC Control fih is-sustanza attiva pantoprazole, li timblokka
l-’pompa’ li tipproduċi l-aċidu
fl-istonku. Għaldaqstant inaqqas l-ammont ta’ aċidu fl-istonku
tiegħek.
SOMAC Control jintuża għal trattament għal żmien qasir ta’
sintomi tar-rifluss (per eżempju qrusa
fl-istonku, rigurġitazzjoni tal-aċidu) fl-adulti.
Rifluss hu fluss lura tal-aċidu mill-istonku għal ġol-gerżuma
(“pajp tal-ikel”), li tista’ ssir infjammata
u tuġgħek. Dan jista’ jikkawżalek sintomi bħal sensazzjoni ta’
ħruq bl-uġigħ fis-sider li jitla ‘l fuq
sal-gerżuma (qrusa fl-istonku) u togħma qarsa fil-ħalq
(rigurġitazzjoni tal-aċidu).
Jista’ jkollok solliev mis-sintomi tar-rifluss tal-aċidu u
tal-qrusa fl-istonku wara jum wieħed biss ta’
trattament b’SOMAC Control, iżda din il-mediċina mhijiex
i
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
SOMAC Control 20 mg pilloli gastro-reżistenti
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull pillola gastro-reżistenti fiha 20 mg ta’ pantoprazole (bħala
sodium sesquihydrate).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola gastro-reżistenti.
Pilloli miksija b’rita, sofor, ovali u bikonvessi stampati
b’“P20” b’linka kannella fuq naħa waħda.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
SOMAC Control hu maħsub għat trattament fuq perjodu ta’ żmien
qasir għas-sintomi ta’ (eż. qrusa
fl-istonku, rigurġitazzjoni tal-aċidu) fl-adulti.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
Id-doża rakkomandata hi ta’ 20 mg ta’ pantoprazole (pillola
waħda) kuljum.
Jista’ jkun neċessarju li tieħu l-pilloli għal 2-3 ijiem
konsekuttivi biex tikseb titjib fis-sintomi.
Ġaladarba jseħħ is-solliev totali tas-sintomi, it-trattament
għandu jitwaqqaf.
It-trattament m’għandux idum iktar minn 4 ġimgħat mingħajr ma
tkellem tabib.
Jekk ma jinkiseb l-ebda solliev tas-sintomi fi żmien ġimagħtejn
ta’ trattament kontinwu, il-pazjent
għandu jingħata struzzjonijiet biex ikellem tabib.
Popolazzjonijiet speċjali
L-ebda aġġustament fid-doża mhu meħtieġ għal pazjenti anzjani
jew dawk b’indeboliment fil-funzjoni
tal-kliewi jew tal-fwied.
_ _
_Popolazzjoni pedjatrika _
SOMAC Control mhux irrakkomandat għall-użu fit-tfal u adolexxenti
ta’ taħt it-18-il sena peress li
m’hemmx biżżejjed informazzjoni dwar is-sigurtà u l-effikaċja.
Metodu ta’ kif għandu jingħata
_ _
SOMAC Control 20 mg pilloli gastro-reżistenti m’għandhomx
jintmagħdu jew jitkissru, u għandhom
jinbelgħu sħaħ mal-likwidu qabel l-ikel.
3
4.3
KONTRAINDIKAZZJONIJIET
Sensittività eċċessiva għas-sustanza attiva jew għal kwalunkwe
sustanza mhux attiva elenkata
fis-sezzjoni 6.1.
Mhux rakkomandat l-għoti ta’ pantoprazole flimkien ma’ impedituri
tal-pr
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 24-05-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 24-05-2023
Public Assessment Report Public Assessment Report Bulgarian 02-05-2013
Patient Information leaflet Patient Information leaflet Spanish 24-05-2023
Public Assessment Report Public Assessment Report Spanish 02-05-2013
Patient Information leaflet Patient Information leaflet Czech 24-05-2023
Public Assessment Report Public Assessment Report Czech 02-05-2013
Patient Information leaflet Patient Information leaflet Danish 24-05-2023
Public Assessment Report Public Assessment Report Danish 02-05-2013
Patient Information leaflet Patient Information leaflet German 24-05-2023
Public Assessment Report Public Assessment Report German 02-05-2013
Patient Information leaflet Patient Information leaflet Estonian 24-05-2023
Public Assessment Report Public Assessment Report Estonian 02-05-2013
Patient Information leaflet Patient Information leaflet Greek 24-05-2023
Public Assessment Report Public Assessment Report Greek 02-05-2013
Patient Information leaflet Patient Information leaflet English 24-05-2023
Public Assessment Report Public Assessment Report English 02-05-2013
Patient Information leaflet Patient Information leaflet French 24-05-2023
Public Assessment Report Public Assessment Report French 02-05-2013
Patient Information leaflet Patient Information leaflet Italian 24-05-2023
Public Assessment Report Public Assessment Report Italian 02-05-2013
Patient Information leaflet Patient Information leaflet Latvian 24-05-2023
Public Assessment Report Public Assessment Report Latvian 02-05-2013
Patient Information leaflet Patient Information leaflet Lithuanian 24-05-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-05-2023
Public Assessment Report Public Assessment Report Lithuanian 02-05-2013
Patient Information leaflet Patient Information leaflet Hungarian 24-05-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 24-05-2023
Public Assessment Report Public Assessment Report Hungarian 02-05-2013
Patient Information leaflet Patient Information leaflet Dutch 24-05-2023
Public Assessment Report Public Assessment Report Dutch 02-05-2013
Patient Information leaflet Patient Information leaflet Polish 24-05-2023
Public Assessment Report Public Assessment Report Polish 02-05-2013
Patient Information leaflet Patient Information leaflet Portuguese 24-05-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 24-05-2023
Public Assessment Report Public Assessment Report Portuguese 02-05-2013
Patient Information leaflet Patient Information leaflet Romanian 24-05-2023
Public Assessment Report Public Assessment Report Romanian 02-05-2013
Patient Information leaflet Patient Information leaflet Slovak 24-05-2023
Public Assessment Report Public Assessment Report Slovak 02-05-2013
Patient Information leaflet Patient Information leaflet Slovenian 24-05-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 24-05-2023
Public Assessment Report Public Assessment Report Slovenian 02-05-2013
Patient Information leaflet Patient Information leaflet Finnish 24-05-2023
Public Assessment Report Public Assessment Report Finnish 02-05-2013
Patient Information leaflet Patient Information leaflet Swedish 24-05-2023
Public Assessment Report Public Assessment Report Swedish 02-05-2013
Patient Information leaflet Patient Information leaflet Norwegian 24-05-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 24-05-2023
Patient Information leaflet Patient Information leaflet Icelandic 24-05-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 24-05-2023
Patient Information leaflet Patient Information leaflet Croatian 24-05-2023

Search alerts related to this product

View documents history